Effects of recombinant human brain natriuretic peptide combined with Sacubitril/Valsartan in treatment of patients with chronic heart failure
Objective:To observe effects of recombinant human brain natriuretic peptide combined with Sacubitril/Valsartan in treatment of patients with chronic heart failure(CHF).Methods:The clinical data of 118 patients with CHF admitted to this hospital from February 2022 to July 2023 were retrospectively analyzed.According to different treatment methods,they were divided into control group and observation group,59 cases in each group.Both groups were given routine treatment.On this basis,the control group was treated with Sacubitril/Valsartan,while the observation group was treated with recombinant human brain natriuretic peptide on the basis of that of the control group.The clinical efficacy,the cardiac function indexes[stroke volume(SV),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD),left ventricular ejection fraction(LVEF),N-terminal pro-brain natriuretic peptide(NT-proBNP)]levels,the vascular endothelial function indexes[endothelin-1(ET-1),nitric oxide(NO),von Willebrand factor(vWF)]levels,the myocardial fibrosis indexes[transforming growth factor-β1(TGF-β1),connective tissue growth factor(CTGF),galectin-3(Gal-3)]levels before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 96.61%(57/59),which was higher than 81.36%(48/59)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of SV and LVEF in the observation group were higher than those in the control group,the levels of LVESD,LVEDD and NT-proBNP were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the level of NO in the observation group was higher than that in the control group,the levels of vWF and ET-1 were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of TGF-β1,CTGF and Gal-3 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Recombinant human brain natriuretic peptide combined with Sacubitril/Valsartan in the treatment of the CHF patients can improve the total effective rate of treatment,improve the levels of cardiac function indexes and vascular endothelial function indexes,and reduce the levels of myocardial fibrosis indexes.Moreover,it is superior to simple Sacubitril/Valsartan treatment.
NETL
NSTL
万方数据
